GlassScriptPhysician profile
Anna C Juncadella
NPI 1467714980
$1,581.79
in general payments reported to CMS, 2019-2025
17 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $115 · 2021: $310 · 2022: $154 · 2023: $316 · 2024: $130 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.05 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.85 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $198.00 | 2020-2021 | |
| Genentech, INC. | $127.33 | 2019 | |
| Janssen Scientific Affairs, LLC | $124.98 | 2019 | |
| Boston Scientific Corporation | $109.50 | 2025 | Exalt Model D |
| Celgene Corporation | $53.82 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $28.69 | 2025 | |
| Ardelyx, INC. | $25.57 | 2025 | Ibsrela |
| Exact Sciences Corporation | $24.83 | 2023 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $23.76 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $19.45 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $17.75 | 2023 | Ocaliva |
| Axonics, INC. | $17.57 | 2023 | Axonics |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.60 | 2020 | |
| Braintree Laboratories, INC. | $14.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Juncadella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.